This article provides clinical and research evidence to support the use of the new NAL-NL3 prescription for hearing aid fittings. By Vicky Zhang, Justin Zakis, Padraig Kitterick, and Brent Edwards Over the past several decades, the National Acoustic Laboratories (NAL) has been leading the development of widely adopted hearing aid prescriptions....
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
Audiologists using NAL-NL2 should monitor adoption timelines and supporting evidence for NAL-NL3; the formula is not yet universally implemented in fitting software, so practice change depends on manufacturer integration and further peer-reviewed validation of clinical outcomes versus NAL-NL2.
NAL-NL3 represents the first major update to the dominant NAL prescription family in over a decade, with machine-learning-derived targets and population-specific modules that could meaningfully shift hearing aid fitting standards worldwide.
- 01NAL-NL3 is developed by Australia's National Acoustic Laboratories, succeeding NAL-NL2 after 10+ years.
- 02The formula incorporates machine learning and optimisation techniques to refine prescriptive gain targets.
- 03Specialised modules include a Comfort in Noise Module and a Minimal Hearing Loss Module.
- 04Additional modules are planned, suggesting an extensible, modular framework rather than a single static formula.
- 05Clinical and research evidence supporting NAL-NL3 is authored by Zhang, Zakis, Kitterick, and Edwards.
NAL-NL3 incorporates 10+ years of real-world data from NAL-NL2 clinical use to improve prescriptive targets.
studypartially supportedNAL-NL3 leverages machine learning and optimisation advances to produce improved hearing aid gain targets.
studypartially supportedNAL-NL3 includes specialised modules for comfort in noise and minimal hearing loss populations.
press releasesupportedNAL-NL3 targets result in better patient outcomes compared to NAL-NL2.
studyunclear- Journal
- Hearing Review
- Publication type
- research_article
- Evidence level
- 2b
- Population
- Adults with hearing loss fitted with hearing aids; clinical and research evidence base used to develop and validate NAL-NL3 targets
- Intervention
- NAL-NL3 hearing aid prescription formula
- Comparator
- NAL-NL2 prescription formula
Primary outcomes
Prescriptive gain targets accuracy vs. preferred listening levels; Patient-reported outcomes in noise and minimal hearing loss populations; Clinical adoption feasibility of NAL-NL3 modules
